PEPCID COMPLETE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PEPCID COMPLETE (PEPCID COMPLETE).
Famotidine competitively inhibits histamine at H2-receptors of gastric parietal cells, reducing gastric acid secretion. Calcium carbonate and magnesium hydroxide act as antacids to neutralize existing gastric acid.
| Metabolism | Famotidine: 30-35% hepatic metabolism (CYP450 not significantly involved); 65-70% renal excretion unchanged. |
| Excretion | Renal: 65-70% (famotidine unchanged); fecal: 30-35% (as metabolites). Biliary elimination is minimal (<5%). |
| Half-life | 2.5-3.5 hours (prolonged to 12-20 hours in severe renal impairment, CrCl <10 mL/min). |
| Protein binding | 15-20% (primarily to albumin). |
| Volume of Distribution | 1.0-1.4 L/kg (suggests distribution into total body water; higher in elderly). |
| Bioavailability | Oral: 40-45% (due to first-pass metabolism; bioavailability reduced by food). |
| Onset of Action | Oral (as chewable tablet): 60 minutes (antisecretory effect). |
| Duration of Action | 10-12 hours (acid suppression persists for 12 hours after a single dose; allows once-daily dosing for GERD). |
One tablet (famotidine 10mg, calcium carbonate 800mg, magnesium hydroxide 165mg) orally once daily, taken 30 minutes before a meal that causes heartburn.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | For CrCl <50 mL/min: reduce famotidine dose by 50% or increase interval to 36-48 hours. Not applicable to antacid component; monitor for magnesium accumulation. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Avoid in severe hepatic impairment due to lack of safety data. |
| Pediatric use | Not approved for use in pediatric patients (<12 years). Safety and efficacy not established. |
| Geriatric use | Consider renal function; may require dose reduction if CrCl <50 mL/min. Monitor for constipation and magnesium toxicity, especially in patients with renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PEPCID COMPLETE (PEPCID COMPLETE).
| Breastfeeding | Famotidine is excreted in breast milk in low concentrations (M/P ratio approximately 0.4-0.8). Antacids are minimally absorbed. Compatible with breastfeeding; use caution if high doses. |
| Teratogenic Risk | Famotidine (PEPCID) in PEPCID COMPLETE: FDA Pregnancy Category B. Animal studies show no fetal harm; no adequate human studies in first trimester. Antacids (calcium carbonate, magnesium hydroxide): Generally considered low risk. No known teratogenic effects in any trimester. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component of the product.
| Precautions | Do not use if you have trouble swallowing, with other acid reducers, or for more than 2 weeks unless directed by a doctor. May mask symptoms of gastric malignancy. Caution in renal impairment. |
Loading safety data…
| Monitor maternal renal function if prolonged use; no specific fetal monitoring required. Monitor for fluid/electrolyte imbalance with high antacid doses. |
| Fertility Effects | No known adverse effects on fertility from famotidine or antacids in animal or human studies. |